AVTX

#2428
Avalo Therapeutics, Inc. - Common Stock
19.2 5 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
19.21
19.28
Jahresspanne
9.54
24.27
Tagesänderung
+1.32%
Monatliche Änderung
+3.22%
6 month change
+5.94%
Jahresänderung
+77.42%
Vorheriger Schlusskurs
19.0 0
Open
19.2 2
Tief
19.2 1
Hoch
19.2 8
Volumen
52
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Avalo Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Avalo Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Avalo Therapeutics, Inc. current report, Q2 FY2026
8-K

Avalo Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Company: Avalo Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2026
Reporting Period: Event-based report for May 5, 2026.
Business Context: The Company is a biopharmaceutical firm focused on developing therapies. This filing reports the announcement of positive topline results from its Phase 2 LOTUS clinical trial evaluating the drug candidate abdakibart for the treatment of moderate to severe hidradenitis suppurativa.

Key Financial Metrics

This Form 8-K is an event-driven report and does not contain audited financial statements, revenue figures, profit data, cash flow statements, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.

Material Changes

There are no financial material changes reported in this document. The material event is the clinical milestone achievement regarding the Phase 2 LOTUS trial results for abdakibart.

Guidance, Outlook, and Management Commentary

  • Event: Announcement of positive topline results from the Phase 2 LOTUS trial.
  • Drug Candidate: Abdakibart.
  • Indication: Moderate to severe hidradenitis suppurativa.
  • Management Commentary: The Company issued a press release and a presentation detailing these results. The filing explicitly states the Company undertakes no obligation to update, supplement, or amend the attached materials.
  • Guidance: No specific financial or operational guidance is provided in this filing.

Investor Verification Checklist

  • Review the full text of the press release (Exhibit 99.1) for specific statistical data regarding the LOTUS trial efficacy and safety.
  • Examine the presentation (Exhibit 99.2) for detailed clinical data and potential next steps for the drug candidate.
  • Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K filing, as this 8-K does not contain financial data.
  • Monitor for any subsequent regulatory filings regarding the Phase 3 trial design or FDA interactions based on these results.

Nachrichten